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Abstract
Background: Altered levels of erythrocyte Na+K+-ATPase, atherogenic and anti-atherogenic lipid
metabolites have been implicated in diabetic complications but their pattern of interactions remains
poorly understood.
This study evaluated this relationship in Nigerian patients with Type 1 diabetes mellitus.
Methods: A total of 34 consented Type 1 diabetic patients and age -matched 27 non-diabetic
controls were enrolled. Fasting plasma levels of total cholesterol, triglycerides and HDL-
cholesterol were determined spectrophotometrically and LDL-cholesterol estimated using
Friedewald formula. Total protein content and Na+K+-ATPase activity were also determined
spectrophotometrically from ghost erythrocyte membrane prepared by osmotic lysis.
Results: Results indicate significant (P < 0.05) reduction in Na+K+-ATPase activity in the Type 1
diabetic patients (0.38 ± 0.08 vs. 0.59 ± 0.07 uM Pi/mgprotein/h) compared to the control but with
greater reduction in the diabetic subgroup with poor glycemic control (n = 20) and in whom cases
of hypercholesterolemia (8.8%), hypertriglyceridemia (2.9%) and elevated LDL-cholesterol (5.9%
each) were found. Correlation analyses further revealed significant (P < 0.05) inverse correlations
[r = -(0.708-0.797] between all the atherogenic lipid metabolites measured and Na+K+-ATPase in
this subgroup contrary to group with good glycemic control or non-diabetic subjects in which
significant (P < 0.05) Na+K+-ATPase and HDL-C association were found (r = 0.427 - 0.489). The
Na+K+-ATPase from the diabetic patients also exhibited increased sensitivity to digoxin and
alterations in kinetic constants Vmax and Km determined by glycemic status of the patients.
Conclusion:  It can be concluded that poor glycemic control evokes greater reduction in
erythrocyte Na+K+-ATPase activity and promote enzyme-blood atherogenic lipid relationships in
Type 1 diabetic Nigerian patients.
Background
Diabetes mellitus, a metabolic disease characterized by
altered carbohydrate, lipid and protein metabolism and
requiring strict glycemic control for delaying or prevent-
ing cardiovascular, nephropathic and neurological com-
plications in humans remains a public health problem in
developing and developed countries of the world [1]. Sev-
eral studies in animals and humans have shown that path-
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ogenic course of both Type 1 and Type 2 diabetes mellitus
involves alterations in the structures, organization and
protein functions of membranes of cells and tissues (e.g.
retina, glomerulli, erythrocyte, nerve), culminating in dia-
betic complications such as retinopathy, nephropathy
and peripheral neuropathy [2-4].
Na+K+-ATPase is a soluble conserved trimeric pump (α,
133 kDa, β, 35 kDa, γ, 10 kDa) involved in transmem-
brane cation regulation via ATP – dependent efflux and
influx of sodium and potassium ions in various cells [5].
The pump is isoenzymic in nature and has its α1 catalytic
subunit encoded by the ATP1A1 gene present in both
erythrocyte and nerve cells [5,6]. Na+K+-ATPase has also
been reported as one of the membrane proteins affected
structurally and functionally in diabetes mellitus [5].
Numerous experimental studies conducted on streptozo-
tocin-induced diabetic rats show that for instance, the
delayed motor nerve conduction velocity, decreased nerve
blood flow, degeneration of peripheral nerves, persistent
hyperglycemia and other metabolic aberrations involve a
common denominator of down-regulated Na+K+-ATPase
[4,7,8]. Reduced activity of Na+K+-ATPase has also been
implicated in streptozotocin-induced diabetic rats with
nephropathy [9]. De Leo et al [10] and Kowluru [11] also
reported impairment in the level of this enzyme in dia-
betic rats and mice with retinopathy. However, in most of
these studies, the observed Na+K+-ATPase reduction was
found with other metabolic derangements which include
myoinositol depletion, aldolase reduction, sorbitol accu-
mulation and protein kinase C activity [7,12]. Subsequent
associations of Na+K+-ATPase with these parameters have
been unfolded [8,12]. Also in humans, several studies
have consistently reported a declined Na+K+-ATPase activ-
ity from the membranes of nerve cells and erythrocytes
preparations of Type 1 and Type 2 diabetic patients cou-
pled with alterations in membrane protein composition
[13-15]. Among diabetic Nigerian patients, defectiveness
in Ca2+  homeostasis and qualitative and quantitative
changes in erythrocyte membrane proteins have also been
reported [16,17]. The work of Okegbile et al [18] also
revealed a reduction in erythrocyte Na+K+-ATPase activity
in Nigerian patients with Type 2 diabetes mellitus similar
to the finding of DeLuise et al [19] in obese patients. The
latter is characterized by dyslipidemia caused by an alter-
ation in the regulations of cholesterol, triglycerides, high
density and low-density lipoproteins [20]. Abnormal lev-
els of these lipids in the blood have subsequently been
observed in diabetics with or susceptible to cardiovascular
complications and microangiopathy [2].
However, research is still needed to enhance our present
understanding about factors responsible for the decreased
Na+K+-ATPase observed in diabetes mellitus especially in
Type 1 diabetes mellitus, which occurs early in life and
requires life-long insulin therapy [1]. Furthermore, this
group of diabetics is also susceptible to cardiovascular
complications of diabetes mellitus [1-4] and in our recent
study we observed microalbuminuria of comparable prev-
alence rates in Type 1 and Type 2 diabetic cohorts and in
whom elevated blood pressure was also found [21].
Understanding the pattern and magnitude of association
between Na+K+-ATPase activity and cardiovascular risk
factors of lipid metabolism would provide a leap forward
in our understanding of how diabetes mellitus progresses
to cardiovascular complications in patients. Clues to this
possibility have emanated from few studies. They include
the observation by Rabini et al [22] that elevated plasma
lysophosphate choline (LPC) due to decreased lecithin-
cholesterol acteyltransferase (LCAT) associate strongly
with reduced Na+K+-ATPase activity in diabetic patients.
Kiziltunc et al [23] also reported cholesterol as an inhibi-
tor of erythrocyte membrane Na+K+-ATPase in vitro.
Inverse correlation between erythrocyte membrane
Na+K+-ATPase activity and polyunsaturated fatty acid lev-
els has also been reported by Djemli-Shipkolye et al, [8].
Taken together, there is currently a paucity data on the
relationship of Na+K+-ATPase with cardiovascular risk fac-
tors such as total cholesterol, triglycerides and low density
lipoprotein cholesterol as well as high density lipoprotein
cholesterol. These lipid metabolites are more synony-
mous with cardiovascular complications than LPC in dia-
betic patients from Nigeria and other parts of the world
21, 24, 25]. Therefore, knowledge of the metabolic effects
of these lipid metabolites on Na+K+-ATPase activity is
essential for a better understanding of the pathogenesis of
diabetes mellitus and evolution of strategies that would
improve the management and prognosis of the disease.
In the present study, erythrocyte ghost membrane prepa-
rations from Nigerian patients with Type 1 diabetes melli-
tus were evaluated for protein content and Na+K+-ATPase
activity in association with duration of diabetes and their
plasma levels of total cholesterol, triglycerides, LDL-cho-
lesterol and HDL-C. The kinetics of the enzyme based on
reaction with ATP in vitro was also investigated.
Methods
Chemicals
All the reagents used in this study were of analytical grade
and highest purity. Fatty acid free bovine serum albumin
(BSA), sodium dodecyl sulfate (SDS), Tris base and diso-
dium salts of adenosine triphosphate (vanadate free), eth-
ylene diamine tetraacetic acid (EDTA), and Ethyleneglycol
– bis-2-aminoethyl ether) N, N, N1, N1 – tetracetic acid
(EGTA) were purchased from Sigma Chemical Co., St.
Louis, MO, U.S.A. Hydrochloric acid (HCl), trichloroace-
tic acid (TCA), sulphuric acid (H2SO4), magnesium chlo-BMC Endocrine Disorders 2007, 7:7 http://www.biomedcentral.com/1472-6823/7/7
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ride (MgCl2), Deoxycholate, potassium chloride (KCl)
and sodium chloride (NaCl) were procured from British
Drug House (BDH), UK. All buffers were prepared to their
respective pH values measured with the aid of a pH meter
(Mettler, Inc. Germany).
Study design
This study enrolled 34 (male/female, 23/11) Type 1 dia-
betic out-patients aged 18 – 37 years attending diabetic
clinics at General Hospital, Lagos, Nigeria. The patients,
diagnosed clinically based on proneness to polydipsia,
polyuria, thirst, weight loss and biochemically based on
sustained hyperglycemia were placed absolutely on a con-
tinuous insulin therapy by attending endocrinologists. A
total of twenty-seven apparently healthy non-diabetic vol-
unteers (male/female, 17/10) were also recruited as con-
trol. Members in the Type 1 diabetes mellitus group were
further subdivided into two subgroups: 'poor glycemic
control group' (fasting glucose > 5.6 mmole/L) (group
A1) and 'good glycemic control group' (fasting glucose ≤
5.6 mmole/L) (group A2). The classification was based on
WHO treatment guidelines [1]. Fasting blood glucose of
members in the control group was also determined twice
at three days interval to ascertain their normoglycemic sta-
tus. Meanwhile, to participate in the study, each member
of the study groups had haematocrit and hemoglobin lev-
els greater than or equal to 33% and 11 g/dl respectively,
no clinical evidence of pancreatitis and gave written
informed consent. Approval to conduct the study was
granted by the ethics review committee of the Hospital
Management Board. Demographic data including age and
duration of diabetics were collected using a questionnaire.
Sample collection and clinical chemistry
Fasting venous blood samples (5 – 7 mL each) were col-
lected between 8.00 and 9.00 h on each clinic day from
the patients and control into labeled heparinized test
tubes. The blood samples were centrifuged at 1,500 g at
25°C for 10 min and the resulting plasma transferred into
plain test tubes for glucose and lipid analysis.
Fasting plasma glucose was determined using a glucome-
ter (ACCU-CHEK Advantage®. Roche Diagnostics Corpo-
ration, IND, USA). Plasma cholesterol and triglycerides
were determined by the enzymatic method of Siedel et al
[26] and McGowan et al [27] respectively. HCL-choles-
terol in plasma was determined following the precipita-
tion of chylomicrons, very low-density lipoproteins
(VLDL), intermediate density lipoproteins (IDL) choles-
terol and low-density lipoprotein (LDL) cholesterol by
MgCl2 – phosphotungstic acid mixture as described by
Lopez-Virrela et al [28]. LDL-cholesterol was estimated
according to Friedewald et al [29]. Hypercholesterolemia
(HCL) was defined as plasma total cholesterol of 200 mg/
dl according to the European Artherosclerosis Society
guidelines [30]. Hypertriglyceridaemia was put at plasma
TAG > 160 mg/dl according to Isselbacher et al, [31]. Ele-
vated LDL-C and reduced HDL-C were defined by values
> 150 mg/dl and < 35 mg/dl respectively [32].
Erythrocyte ghost membrane preparation
A simplified procedure of DeLuise and Flier [33] was used
for erythrocyte ghost membrane preparation. Briefly, 10
volumes of ice cold 5 mM Tris/0.1 mM Na2EDTA, pH 7.6
were added to each of the tubes containing buffy coat free
– packed erythrocytes of diabetics and non-diabetic sam-
ples to achieve osmotic lysis. The resulting membranes
were centrifuged at 20,000 g for 20 min at 4°C. They were
then washed three times in 0.017 M NaCl/5 mM Tris-HCl,
pH 7.6 and three times with 10 mM Tris-HCl (pH 7.5).
The haemoglobin-free membrane suspension was finally
stored at -20°C in the 10 mM washing Tris-HCl buffer
(pH 7.5) but used within three days of preparation for
Na+K+-ATPase assays and membrane protein determina-
tion.
Na+K+-ATPase assays
The erythrocyte total ATPase activity was determined by
incubating 50 µL of ghost membrane suspension (~200
µg of membrane protein) of type 1 diabetic or healthy
subject with 5 mM Tris-ATP, 25 mM KCl, 75 mM NaCl, 5
mM MgCl2, 0.1 mM EGTA, 25 mM Tris-HCl, pH 7.5 in a
total volume of 500 µL for 90 min at 37°C in a shaking
water bath (150 rpm). The reaction was stopped by add-
ing TCA to a final concentration of 5% (wt/vol). After cen-
trifugation for 20 min at 1,500 g, an aliquot of the
supernatant was used to measure total inorganic phos-
phate liberated by the reaction of Fiske and Subbarow
[34]. This assay was repeated in the presence of 200 µM
methyldigoxin, an inhibitor of Na+K+-ATPase activity.
Total ATPase activity was expressed as micromole of inor-
ganic phosphate liberated per milligram membrane pro-
tein per hour. The activity of Na+K+-ATPase was
subsequently determined by subtracting total ATPase
activity in the presence of digoxin from enzyme activity in
the absence of the inhibitor drug.
For the enzymes kinetics experiment, Na+K+-ATPase activ-
ity was measured in assays containing 0.02 – 0.1 mM Tris-
ATP concentration range. A negative control assay devoid
of ghost membrane suspension was run in parallel to the
test assays and used as blank during absorbance measure-
ment at 660 nm. Enzyme activity was then determined as
described previously
The kinetic constants: Vmax and Km were determined by
extrapolation from Lineweaver-Burke plot of reciprocally
transformed activity (V) and substrate (ATP) data.BMC Endocrine Disorders 2007, 7:7 http://www.biomedcentral.com/1472-6823/7/7
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Ghost erythrocyte membrane protein determination
This was determined according to the method of Lowry et
al [35] after solubilizing aliquots of ghost membrane sus-
pension with 0.2% SDS. Bovine serum albumin (BSA) (50
– 300 µg) was used as standard. Absorbance was meas-
ured in a Beckmann D700 spectrophotometer (Beck-
mann, USA) at 720 nm.
Statistical analysis
Data obtained was entered into SPSS statistical software
version 11 for descriptive and deductive statistics and
multivariate regression analyses. All data were expressed
as mean ± SD and analyzed by Student's t-test. The meta-
bolic and demographic parameters obtained were sub-
jected to correlation analysis to test their association with
erythrocyte membrane (Na+K+-ATPase activity. P value
less than 0.05 was regarded as significant.
Results
Demographic and haematological characteristics of the
diabetic and non diabetic subjects are presented in Table
1. The duration of diabetes ranged from 2 to 8 years with
a mean duration of 4.6 years in the type 1 diabetic patients
investigated. No significant (P > 0.05) differences were
noted between the diabetic patients and non-diabetic
control with respect to their age (28.2 ± 3.9 vs. 28.4 ± 4.3
years), haematocrit (39.1 ± 1.4 vs. 39.7 ± 1.2%) and hae-
moglobin levels (13.1 ± 0.3 vs. 13.2 ± 0.2 g/dL).
Compared to the control, significant (P < 0.05) differ-
ences were observed in plasma levels of fasting blood glu-
cose (5.5 ± 0.5 vs. 5.0 ± 0.2 mole/L), total cholesterol
(182.7 ± 12.2 vs. 173.8 ± 7.4 mg/dL), LDL-C (117.2 ± 14.1
vs. 107.6 ± 6.8 mg/dL), HDL-C (38.1 ± 4.7 vs. 42.2 ± 5.3
mg/dL) and triglycerides (137.1 ± 11.3 vs. 120.4 ± 7.5 mg/
dL) in the type 1 diabetic patients investigated. Further
stratification of the diabetic patients revealed significant
disparity in fasting blood glucose (6.1 ± 0.3 vs. 5.2 ± 0.2
mmole/L), total cholesterol (190.3 ± 15.9 vs. 178.4 ± 6.9
mg/dL), LDL-C (128.1 ± 15.1 vs. 111.0 ± 9.3 mg/dL),
HDL-C (33.1 ± 2.6 vs. 40.7 ± 3.5 mg/dL) and triglycerides
(145.3 ± 13.3 vs. 133.4 ± 9.7 mg/dL) between patients
with poor (n = 20) and good (n = 14) glycemia control.
Cases of hypercholesterolemia (3/34, 8.8%), elevated
LDL-C (2/34, 5.9%) and hypertriglyceridemia (1/34,
2.9%) were observed in type 1 diabetic patients who had
their plasma glucose poorly controlled. Reduced plasma
HDL-C levels were observed in 11.1%, 14.7% and 2.9% of
the control, poorly and good glycemia control type 1 dia-
betic subjects studied (Table 2).
Ghost erythrocyte membrane analyses revealed significant
(P < 0.05) difference in protein content (5.4 ± 0.2 vs. 4.6
± 0.4 µg/mL), total ATPase (0.87 ± 0.05 vs. 0.50 ± 0.09
microlePi/mg/h) and Na+K+-ATPase (0.59 ± 0.07 vs. 0.38
± 0.08 microlePi/mg/h) activity between the diabetic
patients and healthy (non-diabetic) controls. The mem-
brane pump (i.e. Na+K+-ATPase also exhibited increased
sensitivity to digoxin compared to the control (75.1 ±
0.07 vs. 65.9 ± 0.05%; P < 0.05). Further analyses revealed
significant (P < 0.05) increases in total ATPase (0.55 ±
0.07 vs. 0.42 ± 0.04 microlePi/mg/h) and Na+K+-ATPase
(0.42 ± 0.07 vs. 0.31 ± 0.04 microlePi/mg/h) activity by
18.7% in Type 1 diabetic patients with good glycemic con-
trol compared to their poor glycemic control counter-
Table 2: Clinical chemistry profiles of the study group
Parameter Control Type 1 diabetic patients
A1 (n = 20) A2 (n = 14) Total
 (n = 34)
FBS, 
mmole/L
5.0 ± 0.2 6.1 ± 0.3ab 5.2 ± 0.2 5.5 ± 0.5a
TC, mg/dL 173.8 ± 7.4 190.3 ± 
15.9ab
178.4 ± 6.9a 182.7 ± 
12.2a
LDL-C, mg/
dL
107.6 ± 6.8 128.1 ± 
15.1ab
111.0 ± 9.3 184.2 ± 
12.6a
HDL-C, 
mg/dL
42.2 ± 5.3 33.1 ± 2.6ab 40.7 ± 3.5 38.1 ± 4.7a
TAG, mg/
dL
120.4 ± 7.5 145.3 ± 
13.3ab
133.4 ± 9.7a 137.1 ± 
11.3a
Hyperchole
sterolemia, 
n(%)
0(0) 3 (8.8) 0(0) 3 (8.8)
Elevated 
LDL-C, 
n(%)
0(0) 2 (5.9) 0(0) 2 (5.9)
Hypertrigly
ceridemia, 
n(%)
0(0) 1 (2.9) 0(0) 1 (2.9)
Reduced 
HDL-C, 
n(%)
3 (11.1) 5 (14.7) 1(2.9) 6 (17.6)
Data are expressed as mean ± SD and analyzed using Student's t-test 
(2-tail).
aP < 0.05 (control vs. IDDM patients), bP < 0.05 (A1 vs. A2). P <0.05 
was considered significant.
Table 1: Demographic and haematological characteristics of the 
study group
Parameter Diabetics Control Statistics
Total number of 
subjects, n(%)
34 (53.7) 27 (46.3) > 0.05
Number of males, n (%) 23 (67.6) 17 (62.9) > 0.05
Number of females, n (%) 11 (32.4) 10 (37.1) > 0.05
Age, years 28.2 ± 3.9 28.4 ± 4.3 > 0.05
†Duration of diabetes, 
years
(2–8) 4.6 ± 
1.5
-N D
Haemoglobin, g/dL 13.2 ± 0.2 13.1 ± 0.3 > 0.05
Haematocrit, % 39.1 ± 1.4 39.7 ± 1.2 > 0.05
†Figures in parenthesis represent range of diabetes duration in the 
patients;  = Chi-square test (χ2);  = Student t- test (Two -tail). P > 
0.05 was regarded as non-significantBMC Endocrine Disorders 2007, 7:7 http://www.biomedcentral.com/1472-6823/7/7
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parts. However, the differences observed in the membrane
protein content (4.6 ± 0.04 vs. 4.6 ± 0.03 µg/mL) and dig-
oxin sensitivity (74.3 ± 0.06 vs. 75.6 ± 0.07%) between
the two diabetic subgroups (A1 and A2) were not signifi-
cant (P > 0.05) (Table 3).
The kinetic profile of erythrocyte Na+K+-ATPase in the
ghost membrane preparations based on reciprocal trans-
formation of data in the Lineweaver-Burk plot is pre-
sented in Figure 1. The Na+K+-ATPase activity with ATP as
a substrate exhibited Vmax of 39.2, 26.3, 16.7 and 16.1
micromole Pi/mg/h in control, good glycemic control,
poor glycemic and all the diabetic patients respectively.
Their respective Km values were 0.454, 0.256, 0.167 and
0.154 mM.
Correlation analyses revealed significant (P < 0.05)
inverse relationship between FBS (r = -0.784), TC (r = -
0.703) and Na+K+-ATPase activity in all the diabetic
patients. In type 1 diabetic patients with poor glycemic
control, an additional inverse significant relationship
between TAG (r = -0.797), LDL-C (r = -0.707) and mem-
brane enzyme activity was found. These associations were
absent in type 1 diabetic patients with good glycemic con-
trol.
An exception being significant relationship between
HDL–C and enzyme activity (r = 0.427; P = 0.048), similar
to observations in non-diabetic control (r = 0.489; P =
0.033) (Table 4).
Discussion
Studies conducted to date in humans and animals have
consistently shown that diabetes mellitus induces a reduc-
tion in erythrocyte membrane Na+K+-ATPase activity,
which results in heamodynamic dysfunction due to
altered microvascular blood flow, rheological abnormali-
ties precipitated by decrease erythrocyte defomability and
raised fluidity and complications such as nephropathy,
neuropathy, cardiovascular disorders and microangiopa-
thy [36,37,1]. The present study has also demonstrated
decreased erythrocyte membrane Na+K+-ATPase activity in
Nigerian patients with type 1 diabetes mellitus. Similar
findings have been reported in previous studies from
other parts of the country involving both type 1 and type
2 diabetic patients [16-18]. However, in these studies the
role of glycemic control and metabolic influence of cardi-
ovascular risk factors such as blood pressure on the mem-
brane enzyme activity were not investigated. Meanwhile,
studies conducted in other countries have observed
decreased enzyme activity in diabetic patients in associa-
tion with microalbuminuria, hyperkalaemia and elevated
serum sialic acid [38,39,14]. In Nigeria, some of these
complications have also been found but independently
among diabetic patients [21,40]. In the present study, we
Lineweaver-Burk plot of erythrocyte membrane Na+K+- ATPase in control and type 1 diabetic patients Figure 1
Lineweaver-Burk plot of erythrocyte membrane 
Na+K+-ATPase in control and type 1 diabetic 
patients. Na+K+-ATPase activity of the ghost erythrocyte 
membrane at 37°C is plotted as a function of inorganic phos-
phate released per mg protein per hour. The intercept on 
the ordinate is equal to 1/Vmax, and the intercept on the 
abscissa is equal to -1/Km. the method of least squares of 
means was used to fit data to the Lineweaver-Burk plot. The 
inset indicates percentage reduction in Vmax and Km values 
of poor glycemic control (A1) and all diabetic patients com-
pared with type 1 diabetic patients with good glycemic con-
trol (A2)
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Table 3: Ghost erythrocyte membrane protein content and 
Na+K+-ATPase activity
Parameter Control Type 1 diabetic patients
A1 (n = 20) A2 (n = 14) A2 (n = 14)
Protein, µg/
mL
5.4 ± 0.2 4.6 ± 0.4a 4.6 ± 0.3a 4.6 ± 0.4a
Total ATPase 
activity 
(micromole Pi/
mg/h)
0.87 ± 
0.05
0.42 ± 
0.04ab
0.55 ± 0.07a 0.50 ± 0.09a
Digoxin 
sensitive 
Na+K+-
ATPase 
activity 
(micromole Pi/
mg/h)
0.59 ± 
0.07
0.31 ± 
0.04ab 
(52.5)
0.42 ± 0.07a 
(71.2)18.7
0.38 ± 0.08a 
(64.4)
‡Digoxin 
sensitivity, %
65.9 ± 
0.05
75.6 ± 0.07a 74.3 ± 0.06a 75.1 ± 0.07a
Data are expressed as mean ± SD and analyzed using Student's t-test 
(2-tail). Figures in parentheses represent Na+K+-ATPase activity in 
diabetic patients as a percentage of control. Figures in superscripts 
indicate percentage increase in Na+K+-ATPase activity in type 1 
diabetics with glycemic control over those with poor glycemic 
control.
‡Digoxin sensitivity is defined as percentage decrease in pump 
activity relative to undigoxinated enzyme,aP < 0.05 (Control vs. Type 
1 diabetic patients), bP < 0.05 (A1 vs. A2). P < 0.05 was considered 
significant.BMC Endocrine Disorders 2007, 7:7 http://www.biomedcentral.com/1472-6823/7/7
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observed the decreased erythrocyte membrane Na+K+-
ATPase activity to have a significant negative correlation
with fasting blood glucose (FBS) and plasma total choles-
terol irrespective of the level of glycemic control in all our
diabetic patients. Our observation with respect to FBS is
supportive of previous findings in which glucose in dia-
betic state exhibited direct toxicity on erythrocyte mem-
brane protein including Na+K+-ATPase through non-
enzymatic glycosylation [41,42]. Although, the level of
glycosylated hemoglobin (HbA1c) was not determined in
our diabetic cohort, the greater FBS-Na+K+-ATPase associ-
ation observed in our patients with poor glycemic control
is suggestive of advanced glycation of the enzyme since
this non-enzymatic process has been associated with
greater reduction in Na+K+-ATPase activity and other cel-
lular signaling proteins such as protein kinase C owing to
their proneness to glycability [43]. The greater reduction
in Na+K+ATPase observed among our type 1 diabetic sub-
group with poor glycemic control may also be due to
greater susceptibility of this protein to oxidative stress
[44]. The fact that glycation can be minimized through
glycemic control as demonstrated in previous studies [9],
there is huge possibility of reducing the magnitude of
Na+K+-ATPase inevitable reduction and subsequent com-
plications in diabetic patients in order to reduce morbid-
ity and mortality rates, currently on the increase in Nigeria
[45]. The poor glycemic control observed in 20 of the 34
patients investigated may not be unconnected with poor
compliance to insulin therapy, the use of which is deter-
mined in part by socioeconomic factors which include
poverty, access to treatment and quality of care in most
developing countries [21]. Our observation of the plasma
total cholesterol as the only cardiovascular risk factor to
correlate negatively with Na+K+-ATPase activity in our dia-
betic cohort irrespective of glycemic control is indicative
of an exceeding clinical importance of this lipid metabo-
lite in type 1 diabetic patients. Earlier studies in this regard
are mostly in vitro in which decreased erythrocyte mem-
brane cholesterol content and cholesterol:phospholipid
ratio were found in erythrocyte ghost preparations from
diabetic patients [8,46]. Since cholesterol modulates
erythrocyte membrane fluidity, its loss into systemic circu-
lation may therefore contribute to the increased fluidity
observed in diabetic patients [37]. However, there is a
strong indication from this study and previous ones that
poor glycemic control may exacerbate the reported choles-
terol loss, which when added to the contributions from
diet and endogenous synthesis may increase the risk of
hypercholesterolemia in diabetes and this we have found
only in our IDDM patients with poor glycemic control.
The same explanation can be adduced for the incidence of
hypertriglyceridemia and elevated LDL-cholesterol in this
group of type 1 diabetic patients since they also exhibited
significant Na+K+-ATPase – TAG/LDL-C association not
found in their good glycemic control counterparts. The
observed significant positive relationship between
enzyme activity and plasma HDL-cholesterol in normal
and type 1 diabetic patients with good glycemic control
validates not only the anti-atherogenic function of this
lipid metabolites but also implicates its presence as a pro-
tective factor against cardiovascular complications in this
subgroup. It raises the possibility of using glycemic con-
trol as a prerequisite for achieving lipid control in type 1
diabetic patients as recently reported by Erciyas et al [47].
Our observed lack of association between duration of dia-
betes, membrane protein and Na+K+-ATPase activity is in
agreement with previous findings [3]. However, Adewoye
et al [17] had previously reported changes in erythrocyte
membrane protein composition in diabetic Nigerians to
involve loss of spectrin and preponderance of ankyrin.
The erythrocyte membrane protein content of 4.3 – 5.1
µgmL in diabetics and 5.5 µg/mL in healthy humans
reported by these workers are comparable to our findings
and thus validate their results. In this study, our non-dia-
betic controls were matched for age with the diabetic
groups to minimize the impact of age on Na+K+-ATPase
activity and validate of the results obtained. Also, the
effect of hematological abnormalities on Na+K+-ATPase
activity [48] was annulled by inclusion of subjects with
Table 4: Correlation analysis between total Na+K+ ATPase activity and other parameters measured in the study group
Na+K+ATPase.(micromolePi/mg/h)
Control Insulin depedent diabetic patients
A1 (n = 20) A2 (n = 14) All patients (n = 34)
F B S rPrPrPrP
-0.18 0.097 -0.963 0.00012* -0.304 0.07 -0.784 0.044*
Duration of diabetes - - 0.173 0.407 0.138 0.425 0.131 0.402
TC -0.03 0.525 -0.722 0.0043* -0.582 0.072 -0.703 0.0047*
LDL-C -0.02 0.454 -0.708 0.0049* -0.613 0.053 -0.628 0.051
HDL:-C 0.489 0.033* 0.199 0.636 0.427 0.038* 0.275 0.077
TAG 0.216 0.187 -0.797 0.0018* -0.368 0.092 -0.582 0.063
Protein 0.100 0.279 0.128 0.537 0.147 0.308 0.291 0.274
*Statistically significant at 0.05 level.BMC Endocrine Disorders 2007, 7:7 http://www.biomedcentral.com/1472-6823/7/7
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hematocrit level ≥ 33% and hemoglobin level of 11 g/dL
and above.
We also observed reduced Vmax for Na+K+-ATPase from
diabetic erythrocyte ghost membrane preparations com-
pared to the control using ATP as the substrate. Also,
greater reduction in the kinetic constant was observed in
poor glycemic control patients. Our data are in concord-
ance with the finding of Okegbile et al [18] in type 2 dia-
betic patients. Reduced Vmax connotes a reduction in the
enzyme ability to hydrolyze ATP in vitro, which undoubt-
edly has physiological implications in the regulation of
transmembrane cation transport in the erythrocytes.
While diabetes may be a factor for this event, numerous
secondary factors have been reported. They include
decreased number of pump units on the erythrocyte
membrane, altered lipid – protein interaction, depleted
membrane anionic charge and enzyme glycation and per-
oxidation [9,10,20,42]. We also observed lower Km val-
ues for the membrane enzyme in our diabetic patients
compared to the control and this suggest increased affinity
for ATP in vitro. This observation is contrary to what Okeg-
bile et al [18] observed in type 2 diabetic patients. How-
ever, Okegbile et al [18] conducted their kinetic assay in
the presence of digoxin and this may explain the differ-
ence in our observations. In this study, assays conducted
in the presence of digoxin were carried out to compare the
sensitivity of Na+K+-ATPase from both diabetic and non-
diabetic subjects to this digitalis. We found the diabetic
enzyme to exhibit an increased sensitivity ranging from
74.3 – 75.6% compared to 69.5% in the non-diabetic
control. This indicates a greater inhibition of diabetic
Na+K+-ATPase enzyme by digoxin similar to observations
with Ouabain [49].
Based on the results of this study, we conclude that the
reduced erythrocyte Na+K+-ATPase activity which occurs
in type 1 diabetes mellitus is exacerbated in Nigerian
patients with poor glycemic control in association with
atherogenic blood lipids.
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